28.34

5.59% 1.50

After Hours: 28.00 -0.34 -1.20%

Beam Therapeutics Inc (BEAM)

Overview News Price History Option Chain Financials Why BEAM Down? Discussions Forecast

Beam Therapeutics Inc stock is traded at $28.34, with a volume of 2.06M. It is up +5.59% in the last 24 hours and up +4.61% over the past month. Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Previous Close:

$26.84

Open:

$26.8

24h Volume:

2.06M

Relative Volume:

0.99

Market Cap:

$2.88B

Revenue:

$352.57M

Net Income/Loss:

$-143.01M

P/E Ratio:

-15.66

EPS:

-1.81

Net Cash Flow:

$-153.40M

1W Performance:

+1.87%

1M Performance:

+4.61%

6M Performance:

+41.63%

1Y Performance:

+7.51%

1-Day Range:

$26.61

$30.50

1-Week Range:

$26.25

$30.50

52-Week Range:

$13.53

$35.25

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name

Beam Therapeutics Inc

Sector

Healthcare (1115)

Industry

Biotechnology (624)

Phone

857-327-8775

Address

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Employee

510

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

BEAM's Discussions on Twitter

Compare BEAM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BEAM Beam Therapeutics Inc	28.34	2.72B	352.57M	-143.01M	-153.40M	-1.81
VRTX Vertex Pharmaceuticals Inc	468.38	113.87B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.54	80.22B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	406.40	52.56B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	803.74	49.31B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	175.07	37.37B	447.02M	-1.18B	-906.14M	-6.1812

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-09-25	Initiated	Jefferies	Buy
Mar-28-25	Upgrade	BofA Securities	Neutral → Buy
Mar-10-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform
Jan-29-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-06-24	Upgrade	Leerink Partners	Market Perform → Outperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jul-23-24	Initiated	H.C. Wainwright	Buy
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral
Dec-08-23	Downgrade	Jefferies	Buy → Hold
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform
Dec-13-22	Initiated	Citigroup	Buy
Jun-17-22	Initiated	BMO Capital Markets	Market Perform
Apr-28-22	Initiated	Credit Suisse	Neutral
Jan-05-22	Initiated	Guggenheim	Buy
Oct-19-21	Initiated	SVB Leerink	Outperform
Sep-24-21	Resumed	Stifel	Buy
Sep-10-21	Initiated	BofA Securities	Buy
May-11-21	Initiated	Redburn	Buy
May-04-21	Initiated	RBC Capital Mkts	Sector Perform
Mar-01-21	Downgrade	Barclays	Overweight → Equal Weight
Feb-16-21	Initiated	Wells Fargo	Overweight
Jan-29-21	Downgrade	JP Morgan	Overweight → Neutral
Jan-06-21	Initiated	Stifel	Hold
Aug-05-20	Initiated	William Blair	Outperform
Mar-02-20	Initiated	Barclays	Overweight
Mar-02-20	Initiated	JP Morgan	Overweight
Mar-02-20	Initiated	Jefferies	Buy
Mar-02-20	Initiated	Wedbush	Outperform

View All

Beam Therapeutics Inc Stock (BEAM) Latest News

12:26 PM

Beam Therapeutics (NASDAQ:BEAM) Shares Up 11.1%What's Next? - MarketBeat

12:26 PM

12:22 PM

Will Beam Therapeutics Inc. stock benefit from infrastructure spendingStock Price Forecasts & Low Cost Wealth Building - bollywoodhelpline.com

12:22 PM

10:31 AM

BofA Adjusts Price Target on Beam Therapeutics to $45 From $43, Maintains Buy Rating - marketscreener.com

10:31 AM

06:48 AM

Beam Therapeutics soars 64% after InvestingPro’s undervalued call in April By Investing.com - Investing.com

06:48 AM

Jan 05, 2026

ARK Invest Boosts Stake in Beam Therapeutics (BEAM) Amid Biotech Focus - GuruFocus

Jan 05, 2026

Jan 04, 2026

Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Jan 04, 2026

Jan 03, 2026

Beam Therapeutics (NASDAQ:BEAM) Rating Increased to Hold at Wall Street Zen - MarketBeat

Jan 03, 2026

Dec 31, 2025

Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? - The Globe and Mail

Dec 31, 2025

Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks - Benzinga

Dec 31, 2025

Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab - TradingView — Track All Markets

Dec 31, 2025